Breast Cancer Therapeutics Market Worth $13.1 billion by 2020 Says a New Research Report at ReportsnReports.com
Dallas, TX (PRWEB) June 07, 2014 -- This report provides in-depth analysis of breast cancer therapeutics market within the eight major geographies of the US, Canada, the top five geographies in Europe (the UK, France, Germany, Spain and Italy) and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.
The breast cancer therapeutics market in the eight major markets The US, The UK, France, Germany, Spain, Italy, Japan and Canada was worth $9.2 billion in 2013, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 5.1% to $13.1 billion by 2020. The US had the largest market in 2013, valued at $5.5 billion, equivalent to a global share of 59%, followed by Japan with $871.5m or 9.4% and Italy with $668.5m or 7.2%. Canada had the lowest market share and value of the leading eight at 2.9% and $268.4m, but is expected to witness rapid growth over the forecast period with a CAGR of 6.7%. This will only be surpassed by Japan, which is expected to witness growth at a CAGR of 6.9%.
Complete report is available at http://www.reportsnreports.com/reports/287909-breast-cancer-therapeutics-in-major-developed-markets-to-2020-approval-of-novel-therapies-to-support-continued-dominance-of-her2-targeted-drugs.html.
Scope
The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer in the major developed markets. The report includes:
• Disease overview, as well as treatment algorithms and treatment usage patterns
• Market size and forecast for the breast cancer market from 2012 to 2019
• Major marketed products for breast cancer along with a heat map of product performance
• In-depth pipeline analysis for global pipeline in breast cancer along with clinical trial failure rate analysis
• Key drivers and restraints that have had and are expected to have a significant impact upon the market
• Key licensing and co-development agreements that could have impact on growth trends
Reasons to buy
The report will enhance your decision-making capability by allowing you to:
• Align your product portfolio to the markets with high growth potential
• Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
• Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the breast cancer therapeutics market
• Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
• Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
Purchase a copy of this report at http://www.reportsnreports.com/purchase.aspx?name=287909.
Few Points from Table of Contents
List of Tables
Table 1: Breast Cancer Therapeutics, Global, Tumor, Nodes and Metastasis Staging, 2010-2013 12
Table 2: Breast Cancer Therapeutics, US, Disease Stage at Diagnosis and Five-Year Relative Survival (%), 2013 13
Table 3: Breast Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013 66
Table 4: Breast Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2013 69
Table 5: Breast Cancer Therapeutics, Global, All Pipeline Products (IND/CTA-Filed and Phase I), 2013 79
Table 6: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013 85
Table 7: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2013 91
Table 8: Breast Cancer Therapeutics, Global, All Pipeline Products (Pre-Registration), 2013 93
Table 9: Breast Cancer Therapeutics, Global, Forecast Data, 2013-2020 94
Table 10: Breast Cancer Therapeutics, US, Forecast Data, 2013-2020 94
Table 11: Breast Cancer Therapeutics, Canada, Forecast Data, 2013-2020 95
Table 12: Breast Cancer Therapeutics, UK, Forecast Data, 2013-2020 95
Table 13: Breast Cancer Therapeutics, France, Forecast Data, 2013-2020 95
Table 14: Breast Cancer Therapeutics, Germany, Forecast Data, 2013-2020 96
Table 15: Breast Cancer Therapeutics, Italy, Forecast Data, 2013-2020 96
Table 16: Breast Cancer Therapeutics, Spain, Forecast Data, 2013-2020 96
Table 17: Breast Cancer Therapeutics, Japan, Forecast Data, 2013-2020 97
List of Figures
Figure 1: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stages I to III, 2013 17
Figure 2: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV, 2013 18
Figure 3: Breast Cancer Therapeutics, Global, Heat Map (Marketed Products) 28
Figure 4: Breast Cancer Therapeutics, Global, Pipeline by Stage of Development and Program Type, 2013 30
Figure 5: Breast Cancer Therapeutics, Global, Pipeline by Molecule Type and Stage of Development, 2013 32
Figure 6: Breast Cancer Therapeutics, Global, Pipeline by Mechanism of Action and Stage of Development, 2013 34
Figure 7: Breast Cancer Therapeutics, Global, Clinical Trial Failure Rate (%), 2013 36
Browse more reports on Pharmaceuticals Market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
Contact sales(at)reportsandreports(dot)com for further information.
About Us:
ReportsnReports.com (http://www.reportsnreports.com/) is an online database of market research reports offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Ritesh Tiwari, Reportsnreports.com, http://www.reportsnreports.com/, +1 (888) 391-5441, [email protected]
Share this article